EVP-ABD

a manganese-based MR contrast agent for hepatic vascular & tissue phase imaging; no other info available 3/03

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Liver Diseases (Liver Disease) 06/01/2008 - "EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model." 06/01/2008 - "Our results indicate that EVP-ABD-enhanced MRI can detect diffuse liver disease generated by CCl(4) based on the significant correlation between proton R1 in liver following EVP-ABD and the CCl(4) doses as well as the histologic scores." 06/01/2008 - "To evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model. "
2.	Hepatitis 06/01/2008 - "To evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model. "
3.	Body Weight (Weight, Body) 12/01/2002 - "Ten Yorkshire pigs (body weight, 26 -46 kg) were used for the efficacy evaluation, nine for kinetic T1 evaluation (three each agent) and one for post EVP-ABD imaging. "